REGiMMUNE Corporation

Industry

  • Biotechnology
    • Large Molecule
      • Antibodies
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
See more in Biomedtracker

Latest on REGiMMUNE Corporation

Scrip

Asia Deal Watch: Cureverse Licenses Option For Neurology Candidate To Angelini

 
• By Joseph Haas, Lisa Takagi, Dexter Jie Yan, and Jung Won Shin

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Angelini Licenses Cureverse’s Nov

Scrip

Deal Watch: Japan’s JCR Inks Pacts With Sumitomo Dainippon, Alexion

 
• By Joseph Haas, Lisa Takagi, Jung Won Shin, and Ian Haydock

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. JCR Signs Deal With Sumitomo On Izcargo

Scrip

Venturing into the Japanese investment market with Mebiopharm

 
• By Ian Haydock

In many ways, Mebiopharm's investment experience is illustrative of the challenges facing the bioventure sector as a whole in Japan, or indeed anywhere else. The need to secure sufficient funding and

Scrip

Astellas moves into vaccine technology through Japanese deal

 
• By Ian Haydock

Astellas has signed an agreement with the Japanese bioventure REGiMMUNE to develop platform technology for the development and delivery of vaccines. The partners said that the collaboration would buil